LDK378, a novel ALK inhibitor approved for advanced-stage non-small cell lung cancer (NSCLC) with ALK gene rearrangement, was recently found to have the effect of blocks 3′3’-cGAMP-induced IFNβrelease in immortalized bone marrow-derived macrophages (iBMDMs). Here, ALK is linked to non-small cell lung carcinoma.